Given that some immunotherapies (e.g., CD20-, EGFR-, IL-1β- or PCSK9-targeting antibodies) were shown to protect from both cancer and atherosclerosis, inflammatory processes and immunity underlying carcinogenesis and atherogenesis may be closely interconnected. This evidence concerns the gene IL1B and cancer.